Nouscom Poster presentation at ASCO 2022

Nouscom Poster presentation at ASCO 2022, reporting the full Phase 1 Data of NOUS-209, an ‘off-theshelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors. NOUS-209 in combination with pembrolizumab is safe, highly immunogenic, and associated with promising early and long-term clinical efficacy in 20 MSI-H GI patients.

• Fakih et al., ASCO 2022 First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI).